Skip to content

Establishment of evidences for usage of sedative drugs in neonates and children: Evaluation of the dosage, efficacy, and safety of midazolam.

Establishment of evidences for usage of sedative drugs in neonates and children: Evaluation of the dosage, efficacy, and safety of midazolam. - Evaluation of the dosage, efficacy, and safety of midazolam.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000000526
Enrollment
75
Registered
2006-11-22
Start date
2006-11-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mechanically ventilated neonates and children.

Interventions

Midazolam

Sponsors

Health and Labour Science Research Grants for Clinical Research on Pediatric disease(Evaluation of the dosage, efficacy, and safety of midazolam)study groups.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Mechanically ventilated neonates and children are included: 1) whose post-conceptional age are between 23 weeks and 15 years old, 2) who are obtained informed consent.

Exclusion criteria

Exclusion criteria: Neonates and children are excluded: 1) who are given paralyzing and sedative drugs continuously. 2) who are given the drugs listed on the drugs do not use. 3) who have severe congenital malformation and chromosomal anomaly. 4) who have neurological disease (ex. severe neonatal asphyxia, severe central nerve impairment, and congenital metabolic diseases) by which it is difficult to evaluate the sedative state. 5) who have severe liver dysfunction, or renal dysfunction. 6) who have hyper reactivity to midazolam and other drugs. 7) who have acute glaucoma. 8) who have severe myasthenia gravis. 9) who are given HIV protease inhibitor, or HIV reverse transcriptase inhibitor. 10) who have alcoholism with shock, come, and depressed vital sign. 11) who have already attended to this study. 12) who are diagnosed not suitable for this study by attending doctors because of their psychological or social factors. 13) who are diagnosed not suitable for this study by attending doctors 14) whose parents change their mind and want not to attend to this study afterward. 15) who are given midazolam by bolus intravenous injection only.

Design outcomes

Primary

MeasureTime frame
Success rate for sedation with midazolam in evaluating sedative state by Ramsay sedation score

Secondary

MeasureTime frame
Adverse event/Pharmacokinetics

Countries

Japan

Contacts

Public ContactYushi Itoh ,MD

National Center for Child Health and Development Division of Neonatology, Department of Perinatology and Maternal Care.

03-3416-0181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026